Is Minimal, [Almost] Steroid-Free immunosuppression a safe approach in adult liver transplantation? :Long-term outcome of a prospective, double blind, placebo-controlled, randomized, investigator-driven study

Annals of Surgery

Volumn 260, Issue 5, 2014, Pages 886-892

  Lerut, Jan P ^a   Pinheiro, Rafael S ^a   Lai, Quirino ^a   Stouffs, Valentine ^a   Orlando, Giuseppe ^a   Rico Juri, Juan Manuel ^a   Ciccarelli, Olga ^a   Sempoux, Christine ^b   Roggen, Francine M ^a   De Reyck, Chantal ^a   Latinne, Dominique ^c   Gianello, Pierre ^d  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d Hepatobiliary Unit Imbanaco Medical center   (Colombia)

Author keywords

Immunosuppression; Liver transplantation; Long term; Pathology; Steroids

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HYDROCORTISONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; STEROID; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ALCOHOL LIVER CIRRHOSIS; BILIARY CIRRHOSIS; CHRONIC GRAFT REJECTION; CHRONIC HEPATITIS; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOLLOW UP; GOUT; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; KARNOFSKY PERFORMANCE STATUS; KIDNEY FAILURE; LIVER GRAFT REJECTION; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MONOTHERAPY; OBESITY; PATIENT SAFETY; PEROPERATIVE CARE; PNEUMONIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; REPERFUSION INJURY; RETRANSPLANTATION; STEROID THERAPY; SURVIVAL RATE; TOXIC HEPATITIS; TREATMENT DURATION; BIOPSY; COMPARATIVE STUDY; FEMALE; LIVER FUNCTION TEST; MALE; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; BIOPSY; DOUBLE-BLIND METHOD; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; PLACEBOS; PROSPECTIVE STUDIES; RECURRENCE; STEROIDS; SURVIVAL RATE; TACROLIMUS; TREATMENT OUTCOME;

EID: 84926122823     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000969     Document Type: Conference Paper

References (50)

1. Starzl TE, Fung JJ. Themes of liver transplantation. Hepatology. 2010;51:1869-1884.
2. Health Resources and Services Administration. 2008 OPTN/SRTRAnnual Report. http://www.ustransplant.org/annualreports/current/ararchives.htm. Accessed September 5, 2014.
3. McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunousuppressant after liver transplantation: A meta-analysis. Am J Transpl. 2006;6:1578-1585.
4. Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl. 2008;14:512-525.
5. Lerut J, Bonaccorsi-Riani E, Finet P, et al. Minimization of steroids in liver transplantation. Transpl Int. 2009;22:2-19.
6. Albano L. Review of clinical trials on minimization and interruption of calcineurin inhibitors and protocols without CNIs in the transplantation of different organs (kidney, heart, and liver)]. Nephrol Ther. 2009;5:S371-S378.
7. Goralczyk AD, Bari N, Abu-Ajaj W, et al. Calcineurin inhibitor sparing with mycophenolatemofetil in liver transplantation: A systematic review of randomized controlled trials. Am J Transplant. 2012;12:2601-2607.
8. Rostaing L, Saliba F, Calmus Y, et al. Review article: use of induction therapy in liver transplantation. Transplant Rev. 2012;26:246-260.
9. Sebagh M, Rifai K, Féray C, et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology. 2003;37:1293-1301.
10. Hübscher SG. What is the long-term outcome of the liver allograft? J Hepatol. 2011;55:702-717.
11. Ekong UD. The long-term liver graft and protocol biopsy: do we want to look? What will we find? Curr Opin Organ Transplant. 2011;16:505-508.
12. Mells G, Mann C, Hubscher S, et al. Late protocol liver biopsies in the liver allograft: A neglected investigation? Liver Transpl. 2009;15:931-938.
13. Oliveira CP, Stefano JT, Alvares-da-Silva MR. Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: A mini review. Expert Rev Gastroenterol Hepatol. 2013;7:361-364.
14. Chak E, Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: A systematic review. Liver Int. 2010;30:1247-1258.
15. Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: A review and guide to management. J Hepatol. 2010;53:199-206.
16. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a non renal organ. N Engl J Med. 2003;349:931-940.
17. KidneyDisease: ImprovingGlobalOutcomes TransplantWork Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9:S1-S155.
18. Duffy JP, Kao K, Ko CY, et al. Long-term patient outcome and quality of life after liver transplantation: Analysis of 20-year survivors. Ann Surg. 2010;252:652-661.
19. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant. 2006;6:1774-1780.
20. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003;361:1502-1510.
21. Lerut J, Mathys J, Verbaandert C, et al. Tacrolimus monotherapy in liver transplantation: One-year results of a prospective, randomized, double-blind, placebo-controlled study. Ann Surg. 2008;248:956-967.
22. Bonaccorsi-Riani E, Sempoux C, Piette N, et al. Impact of steroid-avoidance immune suppression on long-term outcome after liver transplantation for HCV cirrhosis: The need for well documented long-term follow-up. Acta Gastroenterol Belg. 2012;75:411-418.
23. Mukherjee S, Mukherjee U. A comprehensive review of immune suppression used for liver transplantation. J Transplant. 2009;2009:701464.
24. O'Grady JG, Burroughs A, Hardy P, et al. Tacrolimus versus micro-emulsified cyclosporin in liver transplantation: The TMC randomized controlled trial. Lancet. 2002;360:1119-1125.
25. Rodríguez-Perálvarez M, Germani G, Darius T, et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: A systematic review and meta-analysis. Am J Transplant. 2012;12:2797-2814.
26. Margarit C, Bilbao I, Castells L, et al. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: The impact on recurrence of hepatitis C. Transpl Int. 2005;18: 1336-1345.
27. Moench C, Barreiros AP, Schuchmann M, et al. Tacrolimus monotherapy without steroids after liver transplantation: A prospective randomized doubleblinded placebo-controlled trial. Am J Transplant. 2007;7:1616-1623.
28. Chan AJ, Lake JR. Immunosuppression in HCV-positive liver-transplant recipients. Curr Opin Organ Transplant. 2012;17:648-654.
29. Manousou P, Cholongitas E, Samonakis D, et al. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut. 2014;63:1005-1013.
30. Vivarelli M, Dazzi A, Zanello M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation. 2010;89:227-231.
31. Benítez C, Londoño MC, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal instable adult liver transplant recipients. Hepatology. 2013;58:1824-1835.
32. Sebagh M, Samuel D, Antonini TM, et al. Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. J Hepatol. 2012;56:840-847.
33. Demetris AJ, Isse K. Tissue biopsy monitoring of operational tolerance in liver allograft recipients. Curr Opin Organ Transplant. 2013;18:345-353.
34. Stehlik J, Starling RC, Movsesian MA, et al. Cardiac Transplant Research Database Group. Utility of long-term surveillance endomyocardial biopsy: A multi-institutional analysis. J Heart Lung Transplant. 2006;25:1402-1409.
35. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326-2333.
36. Zaydfudim V, Feurer ID, Landman MP, et al. Reduction in corticosteroids is associated with better health-related quality of life after liver transplantation. J Am Coll Surg. 2012;214:164-173.
37. Padbury RT, Gunson BK, Dousset B, et al. Steroid withdrawal from long-term immune suppression in liver allograft recipients. Transplantation. 1993;55:789-794.
38. Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit anti-thymocyte globulin and early tacrolimus monotherapy. Transplantation. 2003;75:1396-1399.
39. Pageaux GP, Calmus Y, Boillot O, et al. Steroid withdrawal at day 14 after liver transplantation: A double-blind, placebo-controlled study. Liver Transpl. 2004;10:1454-1460.
40. Lladó L, Xiol X, Figueras J, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. Am J Transplant. 2007;7:1616-1623.
41. Shapiro R, Jordan ML, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immune suppression with subsequent weaning. Ann Surg. 2003;238:520-525.
42. Duvoux C, Pageaux GP. Immuno suppression in liver transplant recipients with renal impairment. J Hepatol. 2011;54:1041-1054.
43. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial. Am J Transplant. 2012;12:3008-3020.
44. Weiler N, Thrun I, Hoppe-Lotichius M, et al. Early steroid-free immune suppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation. 2010;90:1562-1566.
45. Orci LA, Toso C, Mentha G, et al. Systematic review and meta-analysis of the effect of perioperative steroids on ischaemia-reperfusion injury and surgical stress response in patients undergoing liver resection. Br J Surg. 2013;100:600- 609.
46. Wang C, Sun J, Sheil AG, et al. Short course of methylprednisolone immune suppression inhibits both rejection and spontaneous acceptance of rat liver allografts. Transplantation. 2001;72:44-51.
47. Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation. 2009;87:606-614.
48. Mangus RS, Fridell JA, Vianna RM, et al. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up. Liver Transpl. 2012;18:786-795.
49. Germani G, Pleguezuelo M, Villamil F, et al. Azathioprine in liver transplantation: A reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant. 2009;9:1725-1731.
50. Rodríguez-Perálvarez M, Germani G, Papastergiou V, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol. 2013;58:262-270.